1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly...

Click to read the study in NEJM ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced...

1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with...

1. In this randomized-controlled trial, two 12-day courses of teplizumab improved C-peptide levels compared to placebo at week 78 in...

Click here to read this study in NEJM.  ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced...

Click to read the study in The New England Journal of Medicine ©2024 2 Minute Medicine, Inc. All rights reserved....

1. The hazard ratio for recurrence or death comparing sentinel node biopsy only to completion axillary lymph node dissection was...

Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without...

Click here to read this study in JMIG.  ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be...

Click here to read this study in The New England Journal of Medicine. ©2024 2 Minute Medicine, Inc. All rights reserved. No...